Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Peripheral Nerve-on-a-chip for Predictive Preclinical Pharmaceutical Testing

Award Number: R41TR001270
ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2016
PERIOD OF PERFORMANCE END DATE: 01/31/2017

Group Awards By:

View Award Description

Peripheral Nerve-on-a-chip for Predictive Preclinical Pharmaceutical Testing - ¿ DESCRIPTION (provided by applicant): The drug development pipeline is plagued by unacceptable rates of attrition due in large part to toxicities that are not identified in pre-clincal stages of development. The ability to de-risk lead compounds during pre-clinical development with advanced "organoid-on-a-chip" technologies show tremendous promise. Chemotherapeutics in particular, while clinically effective against a wide array of cancers, are commonly associated with dose-limiting systemic toxicities, causing many patients to alter dose regimens and some to cease treatment altogether. Although the peripheral nervous system bears the brunt of this damage, development of nerve-on-a-chip assays is lagging. Towards that end, the technology described herein allows for 3D growth of high density axonal fiber tracts, resembling peripheral nerve anatomy. Preliminary data demonstrate the feasibility of using microengineered neural tissues that are amenable to morphological and physiological measurements analogous to those of clinical tests. The use of structural and functional analyses should mean chemotherapy-induced neural toxicity will manifest in these measurements in ways that mimic clinical neuropathology. The goal of this proposal is to demonstrate the scientific merit of using changes in the structure-function relationship as an improved measure of peripheral neurotoxicity in vitro. To do this, we will apply chemotherapeutic drugs with known peripheral neurotoxicity, measure physiological endpoints, and compare with morphological changes as well as documented clinical pathophysiology. By analyzing induced changes due to oxaliplatin, paclitaxel, vincristine, and bortezomib, each of which triggers a distinct toxic mechanism of action, we will demonstrate the ability of our model to detect toxicity in a manner currently unavailable to pharmaceutical scientists.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2016	AXOSIM TECHNOLOGIES LLC	1441 CANAL ST	NEW ORLEANS	LA	70112	ORLEANS	USA	National Center for Advancing Translational Sciences	000	1	5/12/2017	NEW	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $224,859 )
2016	2016	AXOSIM TECHNOLOGIES LLC	130 S GENOIS ST	NEW ORLEANS	LA	70119	ORLEANS	USA	National Center for Advancing Translational Sciences	000	1	1/19/2016	NEW	$224,859
														Subtotal = $224,859

Grand Total All Awards = $224,859

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Peripheral Nerve-on-a-chip for Predictive Preclinical Pharmaceutical Testing

Award Number: R41TR001270

ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2016

PERIOD OF PERFORMANCE END DATE: 01/31/2017

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer